Lakefront Biotherapeutics NV (LKFT)

LKFT Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	66.81	87.87	64.24	166.8	508.12	2,233
Short-Term Investments	2,915	2,910	3,053	3,518	3,586	2,470
Cash & Short-Term Investments	2,982	2,998	3,118	3,685	4,094	4,703
Cash Growth	-9.55%	-3.83%	-15.39%	-10.00%	-12.95%	-8.88%
Accounts Receivable	21.74	20.71	47.48	28.45	40.43	111.34
Other Receivables	32.3	31.21	39.88	37.44	26.13	16.83
Total Trade Receivables	54.03	51.91	87.36	65.89	66.56	128.16
Inventory	17.69	22.49	51.19	73.98	52.93	20.57
Other Current Assets	6.77	7	83.33	37.23	23.31	9.95
Total Current Assets	3,061	3,079	3,339	3,862	4,237	4,862
Net Property, Plant & Equipment	76.95	80.66	122.9	126.32	154.25	137.51
Other Intangible Assets	0.75	0.85	164.86	127.91	146.35	60.1
Goodwill	-	-	70.01	69.56	69.81	-
Long-Term Investments	116.3	115.73	295.59	13.58	-	-
Other Long-Term Assets	117.69	129.82	142.91	158.45	127.08	133.69
Total Assets	3,372	3,407	4,136	4,357	4,734	5,193

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	95.77	104.65	98.88	135.2	148.68	137.62
Current Portion of Leases	1.58	1.73	3.48	4.65	7.21	7.2
Unearned Revenue	0.03	0.03	232.48	256.27	365.63	419.87
Other Current Liabilities	3.04	46.46	0.25	32.1	1.02	1.78
Total Current Liabilities	100.42	152.86	335.08	428.22	522.54	566.47
Long-Term Leases	4.85	5.19	8.24	4.94	14.69	19.66
Other Long-Term Liabilities	13.79	12.6	895.46	1,129	1,671	1,964
Total Long-Term Liabilities	18.64	17.79	903.7	1,134	1,686	1,983
Total Liabilities	119.06	170.65	1,239	1,562	2,208	2,550

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	293.94	293.94	293.94	293.94	293.6	292.08
Additional Paid-in Capital	2,737	2,737	2,737	2,737	2,736	2,730
Accumulated Other Comprehensive Income	2.74	3	3.47	-1.2	-1.59	-1.72
Retained Earnings	219.7	201.94	-137.46	-234.16	-501.54	-377.38
Shareholders' Equity	3,253	3,236	2,897	2,796	2,526	2,643
Total Liabilities & Equity	3,372	3,407	4,136	4,357	4,734	5,193

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	6.44	6.92	11.72	9.6	21.9	26.86
Net Cash (Debt)	2,976	2,991	3,106	3,675	4,072	4,676
Net Cash Growth	-9.45%	-3.69%	-15.48%	-9.75%	-12.92%	-8.88%
Net Cash Per Share	45.17	45.39	47.13	55.78	61.98	71.39
Book Value	3,253	3,236	2,897	2,796	2,526	2,643
Book Value Per Share	49.39	49.10	43.96	42.43	38.45	40.36
Tangible Book Value	3,253	3,235	2,662	2,598	2,310	2,583
Tangible Book Value Per Share	49.38	49.09	40.40	39.43	35.16	39.44

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: May 6, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error